Liraglutide + Saline
ApprovedCompleted 0 watching 0 views this week🔥 Hot
84
Development Stage
✓
Pre-clinical✓
Phase 1✓
Phase 2✓
Phase 35
ApprovedIndication / Disease
Type 2 Diabetes Mellitus
Conditions
Type 2 Diabetes Mellitus, Obesity
Trial Timeline
Jan 1, 2012 → Jun 1, 2016
NCT ID
NCT01505673About Liraglutide + Saline
Liraglutide + Saline is a approved stage product being developed by Novo Nordisk for Type 2 Diabetes Mellitus. The current trial status is completed. This product is registered under clinical trial identifier NCT01505673. Target conditions include Type 2 Diabetes Mellitus, Obesity.
Hype Score Breakdown
Clinical
30
Activity
20
Company
9
Novelty
10
Community
12
Clinical Trials (1)
| NCT ID | Phase | Status |
|---|---|---|
| NCT01505673 | Approved | Completed |
Competing Products
20 competing products in Type 2 Diabetes Mellitus